Welcome to our dedicated page for Nektar Therapeutics SEC filings (Ticker: NKTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nektar Therapeutics (NKTR) SEC filings page brings together the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Nektar’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Capital Market, and its filings provide structured insight into clinical progress, capital markets activity and corporate governance.
Recent Form 8-K reports include detailed descriptions of topline results from the Phase 2b REZOLVE-AD trial in atopic dermatitis and the Phase 2b REZOLVE-AA trial in alopecia areata, including study design, patient populations, primary and secondary endpoints, and summarized efficacy and safety outcomes. Other 8-K filings cover financial results for completed quarters, underwritten equity offerings under an effective shelf registration statement, and notices related to Nasdaq minimum bid price compliance.
Through these filings, investors can review how Nektar characterizes rezpegaldesleukin (REZPEG, or NKTR-358) as a first-in-class regulatory T cell stimulator and IL-2 pathway agonist, and how it describes additional pipeline programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. Filings also outline FDA Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata, as well as risk factor language and forward-looking statement disclaimers that frame development and regulatory uncertainty.
On Stock Titan, these SEC documents are updated as they are made available on EDGAR. AI-powered tools can help explain key sections of Nektar’s 8-Ks and related reports in plain language, highlight important clinical and financing disclosures, and surface items such as listing status updates and material agreements. This allows readers to quickly understand the implications of new filings for Nektar’s immunology pipeline and its Nasdaq-listed equity.
Nektar Therapeutics is offering $300,000,000 of common stock and pre-funded warrants in a primary financing to support its drug development programs. Investors may buy common shares or, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share.
The company is a clinical-stage immunotherapy developer with lead autoimmune candidate rezpegaldesleukin and oncology asset NKTR-255. It recently reported positive 52‑week Phase 2b REZOLVE‑AD data in atopic dermatitis, showing sustained EASI‑75, EASI‑90 and itch responses with monthly and quarterly dosing.
Nektar plans Phase 3 trials of rezpegaldesleukin starting in the second quarter of 2026. It estimates approximately $229.1 million in cash and marketable securities as of January 31, 2026, after also raising about $39.4 million via at‑the‑market sales of 673,725 shares at a weighted average price of $58.55.
Nektar Therapeutics is offering $300,000,000 of common stock and pre-funded warrants in a primary financing to support its drug development programs. Investors may buy common shares or, in lieu of shares, pre-funded warrants exercisable for one share at an exercise price of $0.0001 per share.
The company is a clinical-stage immunotherapy developer with lead autoimmune candidate rezpegaldesleukin and oncology asset NKTR-255. It recently reported positive 52‑week Phase 2b REZOLVE‑AD data in atopic dermatitis, showing sustained EASI‑75, EASI‑90 and itch responses with monthly and quarterly dosing.
Nektar plans Phase 3 trials of rezpegaldesleukin starting in the second quarter of 2026. It estimates approximately $229.1 million in cash and marketable securities as of January 31, 2026, after also raising about $39.4 million via at‑the‑market sales of 673,725 shares at a weighted average price of $58.55.
Nektar Therapeutics provided a liquidity update, stating it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This figure is described as an estimate based solely on information available at the time of the announcement.
The company notes that this cash and investment balance is not a comprehensive statement of its operating results or full financial position for that date. The information was furnished under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other securities filings.
Nektar Therapeutics provided a liquidity update, stating it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026. This figure is described as an estimate based solely on information available at the time of the announcement.
The company notes that this cash and investment balance is not a comprehensive statement of its operating results or full financial position for that date. The information was furnished under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other securities filings.
Nektar Therapeutics reported new 36-week maintenance data from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis. Among re-randomized responders, both monthly (Q4W) and quarterly (Q12W) dosing maintained high response rates, including up to 83% maintaining EASI-75 and strong vIGA-AD and itch responses.
A meaningful share of patients also achieved new or deeper responses by Week 52, including increases in EASI-90 and EASI-100 rates, indicating continued improvement with longer treatment. The safety profile over 52 weeks remained consistent with induction, with low discontinuations, mainly mild injection site reactions, and no new safety concerns.
Nektar held an End of Phase 2 meeting with the FDA and reached alignment on a 24 µg/kg Q2W induction dose and co-primary endpoints for two planned Phase 3 registrational trials, which will include a 36-week maintenance period with Q4W and Q12W regimens. The company plans to start Phase 3 in the second quarter of 2026 and is targeting a BLA filing in 2029 based on its broader development plan.
Nektar Therapeutics reported new 36-week maintenance data from its 52-week Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis. Among re-randomized responders, both monthly (Q4W) and quarterly (Q12W) dosing maintained high response rates, including up to 83% maintaining EASI-75 and strong vIGA-AD and itch responses.
A meaningful share of patients also achieved new or deeper responses by Week 52, including increases in EASI-90 and EASI-100 rates, indicating continued improvement with longer treatment. The safety profile over 52 weeks remained consistent with induction, with low discontinuations, mainly mild injection site reactions, and no new safety concerns.
Nektar held an End of Phase 2 meeting with the FDA and reached alignment on a 24 µg/kg Q2W induction dose and co-primary endpoints for two planned Phase 3 registrational trials, which will include a 36-week maintenance period with Q4W and Q12W regimens. The company plans to start Phase 3 in the second quarter of 2026 and is targeting a BLA filing in 2029 based on its broader development plan.
The Vanguard Group reports beneficial ownership of 1,027,089 shares of Nektar Therapeutics common stock, representing 5.04% of the class as of December 31, 2025. Vanguard reports no sole voting or dispositive power, with all 1,027,089 shares held with shared dispositive power and 143,138 shares with shared voting power.
The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Nektar. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report beneficial ownership separately.
Nektar Therapeutics is entering a quiet period starting January 27, 2026 as it prepares analyses of 36-week maintenance data from its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. During this time, the company plans to limit public communications about these data.
The quiet period is described as consistent with Nektar’s prior practices for its REZOLVE studies and planned data disclosures. The next planned investor communication is expected in February 2026, when the company plans to present the maintenance data.
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky reported a planned stock sale under a pre-arranged Rule 10b5-1 trading plan. On January 20, 2026, he sold 3,867 shares of Nektar common stock at a weighted average price of $35.67 per share, through multiple trades within a price range of $35.17 to $36.23. After this transaction, he directly held 21,354 shares of Nektar common stock.
Nektar Therapeutics insider plans to sell common stock under Rule 144. A planned sale of 3,867 common shares through Fidelity Brokerage Services is disclosed, with an aggregate market value of $137,946.37 and 20,341,589 shares of common stock outstanding, to be sold on or about 01/20/2026 on NASDAQ. The shares to be sold were acquired through restricted stock vesting on 08/15/2024, 11/15/2024, and 12/13/2024 as compensation. The notice also reports that Jonathan Zalevsky sold 1,157 common shares on 11/25/2025 for gross proceeds of $68,052.89 during the prior three months.
Nektar Therapeutics reported equity awards to its President & CEO and director on December 22, 2025. The executive received 21,667 shares of common stock through a grant of restricted stock units (RSUs) at a stated price of $0. Each RSU converts into one share of common stock as it vests.
The RSUs vest over four years from the grant date in substantially equal quarterly installments, conditioned on continued service. The filing shows the executive beneficially owning 75,912 shares directly after the transaction and 28 shares indirectly through a spouse. In addition, the executive was granted 86,667 stock options with an exercise price of $43.48, expiring on December 21, 2033, which vest over four years in substantially equal monthly installments based on continued service.
Nektar Therapeutics reported topline 36-week Phase 2b REZOLVE-AA results for its investigational drug rezpegaldesleukin in severe-to-very-severe alopecia areata.
The global study enrolled 92 patients randomized to two rezpegaldesleukin doses or placebo, with mean percentage reduction in SALT score at Week 36 as the primary endpoint. Both active arms more than doubled the SALT reduction seen with placebo, but the primary endpoint narrowly missed statistical significance in the main analysis, with mean reductions of 28.2% and 30.3% versus 11.2% on placebo.
When four patients with major eligibility violations were excluded, both doses met statistical significance, with mean SALT reductions of 29.6% and 30.4% versus 5.7% on placebo. Key secondary measures, including SALT30 and thresholds of SALT≤30, SALT≤20 and SALT≤10, also favored rezpegaldesleukin, though the study was not powered for secondary endpoints. Safety was described as favorable, with mostly mild-to-moderate, self-resolving adverse events, a 1.4% discontinuation rate, and no apparent increase in major cardiovascular, thrombotic or infectious risks compared with placebo.
Nektar Therapeutics reported insider equity activity for its Chief R&D Officer on a Form 4. On November 21, 2025, the officer acquired 2,666 shares of common stock at $0 as restricted stock units vested under the company’s 2017 Performance Incentive Plan, after the compensation committee determined the performance-based condition had been met.
On November 25, 2025, the officer sold 1,157 shares of common stock at a weighted average price of $54.28, solely to cover tax withholding obligations from the RSU vesting, and not as a discretionary trade. Following these transactions, the officer directly held 18,971 shares of common stock. In addition, a stock option for 4,766 shares with a $281.25 exercise price, originally granted in 2020 under the same plan, also became fully vested on November 21, 2025.